Brivudine (trade names Zostex, Mevir, Brivir, a allotment of others) is an antiviral biologic acclimated in the analysis of canker zoster (“shingles”).
Brivudine is acclimated for the analysis of canker zoster in developed patients. It is activated already daily, in adverse to aciclovir, valaciclovir and added antivirals. A abstraction has begin that it is added able than aciclovir, but this has been acknowledged because of a accessible battle of absorption on allotment of the abstraction authors.
Brivudine interacts acerb and in attenuate cases lethally with 5-FU, its prodrugs and accompanying substances. Even topically activated 5-FU can be alarming in aggregate with brivudine. This is acquired by the capital metabolite, bromovinyluracil (BVU), irreversibly inhibiting the agitator dihydropyrimidine dehydrogenase (DPD) which is all-important for inactivating 5-FU. After a accepted brivudine therapy, DPD action can be compromised for up to 18 days. This alternation is aggregate with the carefully accompanying biologic sorivudine which aswell has BVU as its capital metabolite.
There are no added accordant interactions. Brivudine does not decidedly access the cytochrome P450 enzymes in the liver.